Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Data Requested By FDA May Clarify Cancer Risk Reduction Potential

Executive Summary

FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.
Advertisement

Related Content

Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.
Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.
Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal
Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal
Advertisement
UsernamePublicRestriction

Register

PS035363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel